FAS and cancer: -Improved inhibition of cancer cell proliferation and targeted delivery into desired areas.-Enhanced toxicity towards breast cancer cells with Lf-Doxo-MMNPs, supported by IC50 value of 20 μg/mL.-Increased tumor growth inhibition (TGI) in mice treated with Lf-Doxo-MMNPs compared to formulations without Lf and Doxo alone.-Increased TNF-α, Fas, Bax, and caspase-3 expression levels with Lf-Doxo-MMNPs at a concentration of 20 μg/mL.